Neurogene (NGNE) Operating Leases (2019 - 2026)

Neurogene (NGNE) has 8 years of Operating Leases data on file, last reported at $6.1 million in Q1 2026.

• Quarterly Operating Leases fell 29.36% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 29.36% YoY) and the FY2025 annual result came in at $6.8 million, down 27.45% from the prior year.
• Operating Leases declined to $6.1 million in Q1 2026, from $6.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $13.7 million in Q2 2024 to a low of $3.9 million in Q4 2022.
• A 5-year average of $9.5 million and a median of $9.5 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases jumped 292.1% — and 2025, when it plunged 45.52%.
• Tracing NGNE's Operating Leases over 5 years: stood at $3.9 million in 2022, then surged by 213.75% to $12.3 million in 2023, then declined by 23.57% to $9.4 million in 2024, then decreased by 27.45% to $6.8 million in 2025, then decreased by 10.89% to $6.1 million in 2026.
• The last three Operating Leases figures came in at $6.1 million (Q1 2026), $6.8 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.